

Cover Story
Free
With a simplified tech transfer agreement, six industry partners and 15 compounds (but no dedicated research funds), NCI challenges investigators to think creatively.
In Brief


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?” - CBER Director Vinay Prasad dared to “say no to drugs”
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Robert A. Winn named director of Fox Chase Cancer Center
- Early-onset colorectal cancer demands a new research playbook











